1Wang Y N, Yamaguchi H, Hsu J M, et al. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins [J]. Oncogene, 2010,29(28): 3997-4006.
2Pallis A G, Karamouzis M V, Konstantinopoulos P A, et al. Molecular networks in respiratory epithelium carcinomas [J]. Cancer Lett, 2010,295 (1):1-6.
3De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment [J]. J Cellular Physiol, 2008,214(3) : 559-5678.
4Ranson M, Hammond L A, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor- tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial [J]. J Clin Onco, 2002, 20 (9) : 2240-2250.
5Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J]. J Clin Onco, 2002,20(21): 4292-4302.
7Herbst R S, Maddox A M, Rothenberg M L, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well- tolerated and has activity in non-small- cell lung cancer and other solid tumors:results of a phase I trial [J]. J Clin Oncol, 2002,20 (18) : 3815 - 3825.
8Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors[J1. Annals Oncol, 2003,14 (6) : 922- 930.
9Fukuoka M, Yano S, Giaccone G. Multi-institutional randomized phase II trial of gefitinib for prevlously treated patients with advanced non-small-cell lung cancer (The DEAL I Trial) [corrected] [J]. J Clin Oncol,2003, 21 (12) :2237-2246.
10Kris M G, Natale R B, Herbst R S, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyorsinekinase, in symptomatic patients with non-small cell lung cancer: randomized tfial [J]. JAMA, 2003, 290(16) : 2149-2158.
5Ritter C A, Arteaga C L. The epidermal growth factor receptor- tyrosine kinase: a promising therapeutic target in solid tumors [ J ]. Semin Oncol, 2003,30 ( 1 ) : 3-11.
6Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N Engl J Med, 2009,361 (10) :947-957.
7Perez-Soler R, Sahz L. Cutaneous adverse effects with HERI! EGFR-targeted agents: is there a silver lining [J]? J Clin Oncol, 2005,23 (22) : 5235-5246.
8Perez-Soler R, Delord J P, Halpern A, et al. HERI/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum [J]. Oncologist, 2005,10(3) :345-356.
9Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors [J]. Ann Oncol, 2005,16(9) : 1425-1433.
10Laeouture M E, Lai S E. The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome [J]. Br J Dermatol, 2006, 155 (6) : 852-854.
7Kim S T. Randomized phase II study of gefitinib versus erlotinib in pa-tients with advanced non small cell lung cancer who failed previousehemotherapy[J]. Lung Cancer, 2012, 75 ( 1 ) : 82-88.
8Heist RS, Engelman JA. SnapShot: non-small cell lung cancer [ J ]. Cancer Cell, 2012, 21 (3) : 448. e2.
9Takamochi K, Suzuki K, Sugimura H, et al. Surgical resec- tion after gefitinib treatment in patients with lung adenocarci- noma harboring epidermal growth factor receptor gene mutation[ J]. Lung Cancer, 2007, 58( 1 ) : 149-155.
10Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer [J ]. N Engl J Med, 2005, 353(2) :123-132.
